fbpx

ABOUT VHIO

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:

DISCOVER MORE

PROGRAMS & GROUPS

Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits for patients.

MEET VHIO´S TEAMS

NEWS

VHIO to incorporate Guardant Health’s breakthrough liquid biopsy technology in 2021

18/01/2021|Comments Off on VHIO to incorporate Guardant Health’s breakthrough liquid biopsy technology in 2021

A step forward in the validation of reliable preclinical models for cancer research

08/01/2021|Comments Off on A step forward in the validation of reliable preclinical models for cancer research

Seeking out predictive biomarkers for a longer-term response to immunotherapy against NSCLC

31/12/2020|Comments Off on Seeking out predictive biomarkers for a longer-term response to immunotherapy against NSCLC

The promise of KEYNOTE-177: Nature Reviews Clinical Oncology’s Research Highlight with invited comment from Josep Tabernero

29/12/2020|Comments Off on The promise of KEYNOTE-177: Nature Reviews Clinical Oncology’s Research Highlight with invited comment from Josep Tabernero

Vall d’Hebron researchers publish a review on the influence of radiotherapy and cancer surgery on the immune system

16/12/2020|Comments Off on Vall d’Hebron researchers publish a review on the influence of radiotherapy and cancer surgery on the immune system

Peptomyc announces new equity financing round led by Aurora Science

16/12/2020|Comments Off on Peptomyc announces new equity financing round led by Aurora Science

SEE ALL NEWS

Follow us:

DIRECTION &
PRINCIPAL INVESTIGATORS

Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.

BROWSE OUR PIS

SCIENTIFIC
REPORT
2019

LAUNCH

CLINICAL TRIALS

Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic:

CLINICAL TRIALS OFFICE
RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER (UITM) – “LA CAIXA” FOUNDATION
CURRENTLY OPEN TRIALS

PROJECTS & INSTITUTIONAL PROGRAMS

Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s Scientific Coordination Area:

CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM
BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI)
“LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM
SCIENTIFIC COORDINATION

EVENTS

VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree:

VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES
INTERNATIONAL SYMPOSIA
WORKSHOPS & COURSES
BENCHSTORMING SEMINARS